Trump Orders $50M Research into Psychedelic Drugs for PTSD, TBI

The executive order aims to explore potential treatments using ibogaine and other psychedelics.

Apr. 18, 2026 at 5:05pm

Got story updates? Submit your updates here. ›

A vibrant neon outline of a human brain with pulsing electrical currents, conceptually representing the potential of psychedelic drugs to treat neurological and mental health conditions.The federal government's new research initiative aims to unlock the therapeutic potential of psychedelics for treating PTSD, TBI, and other mental health issues.Fort Lauderdale Today

President Donald Trump has signed an executive order directing the federal government to allocate $50 million in funding for research into psychedelic drugs, including ibogaine, as potential treatments for post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI).

Why it matters

This move represents a significant shift in the federal government's stance on psychedelic drugs, which have historically been tightly regulated and restricted. The order reflects growing scientific interest in the therapeutic potential of these substances, particularly for addressing mental health issues affecting military veterans and others.

The details

The executive order calls for the Department of Health and Human Services, the Department of Defense, and the Department of Veterans Affairs to coordinate research efforts on psychedelics like ibogaine, psilocybin, and MDMA. Ibogaine, in particular, has shown promise in early studies for treating addiction and PTSD, though it remains illegal at the federal level.

  • President Trump signed the executive order on April 18, 2026.

The players

President Donald Trump

The 45th President of the United States who signed the executive order directing increased federal research into psychedelic drugs.

Got photos? Submit your photos here. ›

What they’re saying

“We must explore every avenue to help our veterans and others suffering from the invisible wounds of war. Psychedelics may hold the key to breakthrough treatments, and the federal government has a responsibility to lead the way on this research.”

— President Donald Trump

What’s next

The executive order directs federal agencies to establish a joint task force to oversee the research program and report back to the President within 180 days on the progress and findings.

The takeaway

This executive order represents a significant shift in the federal government's stance on psychedelic drugs, reflecting growing scientific interest in their potential therapeutic benefits for addressing mental health issues like PTSD and TBI. The research program could lead to new treatment options for veterans and others in need.